Cinacalcet use in pediatric chronic kidney disease

References

1. ↵
   1. Cunningham J,
   2. Locatelli F,
   3. Rodriguez M

   (2011) Secondary hyperparathyroidism:pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. El DS,
   2. Farag YM,
   3. Safdar E,
   4. Shalaby MA,
   5. Singh AK,
   6. Kari JA

   (2016) Prevalence of hyperparathyroidism, mineral and bone disorders in children with advanced chronic kidney disease. Indian J Pediatr 83:420–425.

   OpenUrl
3. ↵
   1. Sanchez CP

   (2003) Secondary hyperparathyroidism in children with chronic renal failure:pathogenesis and treatment. Paediatr Drugs 5:763–776.

   OpenUrlPubMed
4. ↵
   1. Torres PA,
   2. De BM

   (2012) Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 82:19–25.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Kawata T,
   2. Tokunaga S,
   3. Murai M,
   4. Masuda N,
   5. Haruyama W,
   6. Shoukei Y,
   7. et al.

   (2018) A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One 13:e0195316.

   OpenUrl
6. ↵
   1. Wada M,
   2. Furuya Y,
   3. Sakiyama J,
   4. Kobayashi N,
   5. Miyata S,
   6. Ishii H,
   7. et al.

   (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977–2983.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Palmer SC,
   2. Nistor I,
   3. Craig JC,
   4. Pellegrini F,
   5. Messa P,
   6. Tonelli M,
   7. et al.

   (2013) Cinacalcet in patients with chronic kidney disease:a cumulative meta-analysis of randomized controlled trials. PLoS Med 10:e1001436.

   OpenUrlCrossRefPubMed
8. ↵
   1. Ballinger AE,
   2. Palmer SC,
   3. Nistor I,
   4. Craig JC,
   5. Strippoli GF

   (2014) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 12:CD006254.

   OpenUrlPubMed
9. ↵
   1. Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)

   (2011) Kidney Int Suppl 2017(7):1–59.

   OpenUrl
10. ↵
    1. Bacchetta J,
    2. Schmitt CP,
    3. Ariceta G,
    4. Bakkaloglu SA,
    5. Groothoff J,
    6. Wan M,
    7. et al.

    (2020) Cinacalcet use in paediatric dialysis:a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA. Nephrol Dial Transplant 35:47–64.

    OpenUrl
11. ↵
    1. Alharthi AA,
    2. Kamal NM,
    3. Abukhatwah MW,
    4. Sherief LM

    (2015) Cinacalcet in pediatric and adolescent chronic kidney disease:a single-center experience. Medicine (Baltimore) 94:e401.

    OpenUrl
12. 1. Silverstein DM,
    2. Kher KK,
    3. Moudgil A,
    4. Khurana M,
    5. Wilcox J,
    6. Moylan K

    (2008) Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol 23:1817–1222.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Platt C,
    2. Inward C,
    3. McGraw M,
    4. Dudley J,
    5. Tizard J,
    6. Burren C,
    7. et al.

    (2010) Middle-term use of Cinacalcet in paediatric dialysis patients. Pediatr Nephrol 25:143–148.

    OpenUrlCrossRefPubMed
14. ↵
    1. Dotis J,
    2. Printza N,
    3. Ghogha C,
    4. Papachristou F

    (2013) Short- and middle-term continuous use of cinacalcet in children on peritoneal dialysis. J Pediatr Endocrinol Metab 26:39–43.

    OpenUrl
15. ↵
    1. Warady BA,
    2. Iles JN,
    3. Ariceta G,
    4. Dehmel B,
    5. Hidalgo G,
    6. Jiang X,
    7. et al.

    (2019) A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol 34:475–486.

    OpenUrl
16. ↵
    1. Morales AJ,
    2. DeFreitas MJ,
    3. Katsoufis CP,
    4. Seeherunvong W,
    5. Chandar J,
    6. Zilleruelo G,
    7. et al.

    (2019) Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease. Pediatr Nephrol 34:129–135.

    OpenUrl
17. ↵
    1. Cinacalcet hydrochloride tablet, coated

    Highlights of prescribing information [cited 2017], Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021688s023lbl.pdf.
18. ↵
    1. Thomson K,
    2. Hutchinson DJ,
    3. Chablani L

    (2018) Stability of extemporaneously prepared cinacalcet oral suspensions. Am J Health Syst Pharm 75:e236–e240.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

    (2009) Kidney Int Suppl 113:S1–S130.

    OpenUrlPubMed
20. ↵
    1. Foley CM,
    2. Polinsky MS,
    3. Gruskin AB,
    4. Baluarte HJ,
    5. Grover WD

    (1981) Encephalopathy in infants and children with chronic renal disease. Arch Neurol 38:656–658.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. Woodard-Knight L,
    2. Fudge A,
    3. Teubner J,
    4. Simmer K

    (1992) Aluminium absorption and antacid therapy in infancy. J Paediatr Child Health 28:257–259.

    OpenUrlPubMed
22. ↵
    1. Block GA,
    2. Hulbert-Shearon TE,
    3. Levin NW,
    4. Port FK

    (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients:a national study. Am J Kidney Dis 31:607–617.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Susantitaphong P,
    2. Vadcharavivad S,
    3. Susomboon T,
    4. Singhan W,
    5. Dumrongpisutikul N,
    6. Jakchairoongruang K,
    7. et al.

    (2019) The effectiveness of cinacalcet:a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail 41:326–333.

    OpenUrl